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The greater antiproteinuric efficacy of converting enzyme
inhibitor and angiotensin II receptor blocker combination
(CEIþARB), versus monotherapy with either drug, is not
a consistent finding. We evaluated the clinicopathologic
predictors of response to CEIþARB in 43 patients with
primary glomerulonephritis (GN), never treated with
immunosuppressive drugs, and with persistent proteinuria
after CEI alone. Main histological lesions were analyzed by
obtaining on 557 glomeruli and 165 arteries formal score of
mesangial cellularity, glomerulosclerosis, tubulointerstitial
damage, mononuclear cell infiltration, arteriosclerosis, and
arteriolar hyalinosis. Duration of CEI and CEIþARB therapy
was similar (4.772.4 and 5.071.5 months). Proteinuria
(g/day) decreased from 3.572.9 to 2.472.3 after CEI, and
to 1.571.3 after CEIþARB (Po0.0001). Reduction of
proteinuria after CEIþARB was greater in proliferative
versus non-proliferative GN (63.3723.4 versus
42.4723.7%, respectively; P¼ 0.006). When patients were
categorized in responders and non-responders to CEIþARB,
no difference between the two groups was detected in any
demographic or clinical variable, whereas histology showed
in responders a greater prevalence of proliferative GN (71.4
versus 31.8%, P¼ 0.009) and higher score of mesangial
cellularity (1.7670.53 versus 1.2070.22, Po0.0001). At
multiple regression analysis (r2¼ 0.476, P¼ 0.001), response
to CEIþARB resulted independently related only to
mesangial cellularity (Po0.0001). In conclusion, the best
independent predictor of antiproteinuric efficacy of
CEIþARB in patients with primary GN is the degree of
mesangial cellularity. This finding supports the experimental
evidence that high angiotensin II contributes to proliferation
of mesangial cells.
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The worldwide expansion of population with chronic kidney
disease (CKD), the high cost of renal replacement therapies,
and their scarce availability in underdeveloped countries as
well, have made imperative a major change in the clinical
approach to CKD from treatment of advanced stages to
much more aggressive primary and secondary prevention.1
According to this goal, reduction of proteinuria has become
the cornerstone of conservative treatment of CKD;2,3 protei-
nuria, in fact, is now recognized as the main independent
determinant of onset and progression of renal insufficiency.4,5
As angiotensin II (AII), proteinuria, and worsening of renal
function are intimately connected,4–6 it has been proposed to
maximize inhibition of renin–angiotensin system (RAS) to
the antiproteinuric effect and to start such a treatment early in
the course of disease, that is, well before the development of
overt renal insufficiency.2–4,7
Dual blockade of RAS, by combining converting enzyme
inhibitors (CEI) with AII type 1 receptor blockers (ARB), has
stimulated a great interest in the nephrology community as
small-scale clinical studies have documented, on average, a
greater antiproteinuric effect of combination treatment, as
compared to monotherapy with either CEI or ARB, in
patients with different chronic renal diseases.8–10 The
therapeutic advantage has been strengthened by the large
combination treatment of angiotensin II receptor blocker and
angiotensin-converting enzyme inhibitor in non-diabetic
renal disease (COOPERATE) trial that demonstrated halving
of risk of end-stage renal failure of dual blockade versus
monotherapy with either CEI or ARB.11
The larger antiproteinuric response to combination
therapy in patients with glomerulonephritis (GN), however,
is not a consistent finding. In patients with either
membranous nephropathy or focal-segmental glomerulo-
sclerosis,12 our group did not confirm the higher efficacy of
this intervention observed in immunoglobulin A nephro-
pathy (IgAN).8,9 Heterogeneous response to combined
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treatment was also hypothesized by the investigators of the
COOPERATE trial.11 Whether the different antiproteinuric
effect is related to the type of renal lesions or clinical
characteristics of patients, or changes of systemic or renal
hemodynamics during treatment, remains undefined. This
point is crucial because maximal suppression of RAS is costly
and not totally exempt from relevant side effects, such as
hyperkalemia and acute renal failure.10 Knowledge of clinical
and histological predictors of high antiproteinuric response
to CEI and ARB combination is also critical to gain more
insights into the mechanisms underlying the superiority of
dual blockade of RAS. This information may encourage
nephrologists at identifying and treating the patients who will
potentially gain most benefit from combined therapy.
Nowadays, in fact, less than 5% of CKD patients regularly
followed by nephrologists are receiving co-administration of
CEI and ARB in spite of significant proteinuria.13,14
This study was aimed at evaluating the potential
demographic, clinical, and morphological (type and severity
of renal lesions) predictors of antiproteinuric response to
CEIþARB in patients with a variety of primary GNs and
persistent proteinuria after CEI alone.
RESULTS
Seventy-two patients were selected on the basis of inclusion
criteria. We excluded 15 patients treated with steroids or
immunosuppressive agents, two patients who started CEI
more than 6 months after biopsy, three patients treated for
less than 2 months with either CEI or CEIþARB, three
patients with inadequate biopsy specimen, and six patients
with incomplete data collection and/or inaccurate 24-h urine
collection. Forty-three patients were therefore included in the
final analysis. Histological scores were obtained on 557
glomeruli and 165 arteries. A good agreement between the
two observers in scoring histological lesions was testified by
kappa index 40.75 for all the examined scores.
Demographic and clinical characteristics of enrolled
patients, which were not different from those of excluded
patients (data not shown), are reported in Table 1. All
patients had proteinuria 41 g/day at the time of renal biopsy.
When patients were categorized on the basis of type of
glomerular lesion traditionally prominent (proliferative or
non-proliferative GN), patients with proliferative GN were
characterized by younger age, lower proteinuria, and higher
serum albumin level, as well as by higher score of mesangial
cellularity (Table 2).
In the whole group of patients, combination therapy was
more effective than CEI in decreasing proteinuria
(53.1725.5 versus 28.3728.7%, Po0.0001). In particu-
lar, as depicted in Figure 1, the percentage decrement of
proteinuria after CEIþARB was significantly greater in
proliferative than in non-proliferative GNs. As expected, the
difference disappeared when considering the absolute reduc-
tion (1.5571.53 and 2.4772.78 g/day, respectively;
P¼ 0.191) because of the different basal levels of proteinuria.
The antiproteinuric response to combination did not
correlate with basal proteinuria (r¼0.151, P¼ 0.335); the
same held true when examining separately proliferative and
non-proliferative GNs. Similarly, it did not differ between
patients with and without nephrotic proteinuria (X3.5 g/
day) at baseline (56.4724.3 and 51.3726.4%, respec-
tively; P¼ 0.438). Finally, the efficacy of combination
treatment was not influenced by the specific diagnosis of
IgAN; in this subclass of GN, in fact, entity of proteinuria
reduction after CEIþARB was analogous to that found in
the other GNs (59.3720.2 and 49.4727.9%, respectively;
P¼ 0.227).
As reported in Table 3, the progressive decrement of
proteinuria was associated with a slight but significant
improvement of serum albumin levels. Both systolic and
diastolic blood pressure (BP) were diminished by CEI and by
CEIþARB; however, the entity of systolic/diastolic BP
reduction did not significantly differ between monotherapy
and combined therapy (CEI: 6.5712.2/3.2713.5%;
CEIþARB: 9.1710.0/6.179.3%). Estimated glomerular
filtration rate (GFR) also diminished after combination
therapy, but, again, the changes were similar to those
observed after CEI alone. Neither hemoglobin nor serum
potassium was affected by the magnitude of RAS inhibition.
Daily sodium excretion did not differ from baseline to
CEIþARB, testifying a constant salt intake in the three
periods (10.574.2, 10.673.6, and 10.575.4 g NaCl/day).
The administered CEIs were ramipril (n¼ 25, mean dose:
5.671.7 mg/day, range: 5–10), enalapril (n¼ 10, mean dose:
19.073.2 mg/day, range: 10–20), and lisinopril (n¼ 8, mean
dose: 18.873.5 mg/day, range: 10–20). The three CEIs used
had the same antiproteinuric effect (P¼ 0.521). In the
combination therapy, two different ARBs were added, while
maintaining unchanged type and dose of CEI; specifically,
irbesartan was used in 29 patients (mean dose: 295728 mg/
day, range: 150–300) and losartan in 14 patients (mean dose:
89721 mg/day, range: 50–100). Similarly to CEI, add-on
therapy with either ARB led to analogous antiproteinuric
response (P¼ 0.209). Type and dose of other antihyper-
tensive drugs, prescribed in six patients (furosemide n¼ 1,
amlodipine n¼ 3, doxazosin n¼ 2), did not change through-
out the study.
When patients were divided in responders and non-
responders to CEIþARB (Table 4), no major clinical
difference, except for the extent of proteinuria reduction,
became manifest. Also, the duration of combined therapy was
Table 1 | Demographic and clinical characteristics of patients
Gender (M:F) 28:15
Age (years) 38.2716.1
Body mass index (kg/m2) 26.174.0
Proteinuria (g/day) 3.5172.85
Serum creatinine (mg/dl) 1.0370.27
Duration of CEI alone (months) 4.772.4
Duration of CEI+ARB (months) 5.071.5
ARB, angiotensin II receptor blocker; CEI, converting enzyme inhibitor; F, female;
M, male.
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similar (5.271.6 and 4.871.4 months, P¼ 0.480). On the
other hand, when examining the histological patterns of
biopsies (Table 5), the responder group was characterized by
greater prevalence of proliferative GNs and higher score of
mesangial proliferation than non-responder group, whereas
severity of other renal lesions did not differ. In agreement
with the observation of a similar entity of Uprot reduction
after CEIþARB in patients with and without IgAN, the
prevalence of IgAN did not differ between responders and
non-responders (P¼ 0.287). Correlation analysis demon-
strated that the extent of antiproteinuric response to
CEIþARB and mesangial score were strictly associated
(r¼ 0.573, Po0.0001); this association similarly occurred
in proliferative (r¼ 0.501) and non-proliferative (r¼ 0.512)
glomerulonephritides (Figure 2). On the basis of these
results, we used multiple regression analysis to determine the
independent role of the main potential predictors of
antiproteinuric response to CEIþARB (Table 6). This
analysis, which explained almost 50% of variance of percent
change of proteinuria, identified mesangial score as the sole
independent predictor of antiproteinuric response to combi-
nation therapy.
DISCUSSION
Suppression of AII activity is the main intervention indicated
to reduce proteinuria and retard progression of renal disease
in CKD patients.2,3,15 However, CEI alone allows only a
modest reduction of proteinuria and does not satisfactorily
reduce progression toward end-stage renal disease.6–12,16 A
likely explanation derives from experimental evidence that
concentration of AII is much higher in the kidney than in
plasma,17 and that CEI administration, while completely
inhibiting systemic AII production, does not significantly
affect intrarenal AII because most of it is formed via non-
angiotensin-converting enzyme-dependent pathways, such
as that of chymase.17,18 This hypothesis has been confirmed
by clinical studies that evidenced in the human kidney
the predominant role of angiotensin-converting enzyme-
independent generation of AII in states of elevated RAS
activity.10,19–21 Noteworthy, a similarly moderate nephropro-
tective efficacy has been found for ARBs,8–12 likely because in
the course of ARB monotherapy, the high AII concentrations
reached can overcome inhibition of type 1 AII receptor.10 On
the contrary, in the presence of activated RAS, maximal
reduction of intrarenal AII has been obtained by combining
low doses of CEIþARB, with the decrement being greater
than that observed after administration of higher doses of
either agent alone.22 Overall, these data support the use of
combined treatment in conditions characterized by high
intrarenal AII levels. This study verifies, for the first time in
patients with various biopsy-proven primary GNs, the
validity of this rationale behind the administration of
CEIþARB.
When considering the whole group of subjects, reduction
of proteinuria after CEIþARB was almost the double than
Table 2 | Comparison of main basal clinical and pathological
features in patients with proliferative (n=22) and
non-proliferative GN (n=21)
Proliferative
GN
Non-proliferative
GN P-value
Diagnosis IgAN (n=16) MN (n=13) —
MesP (n=5) FSGS (n=7) —
MP (n=1) MC (n=1) —
Age (years) 31.8712.6 44.8717.1 0.007
Male gender (%) 59.1 71.4 0.396
Proteinuria (g/day) 2.2771.49 4.8073.35 0.004
Serum creatinine (mg/dl) 1.0170.31 1.0570.24 0.637
eGFR (ml/min/1.73 m2) 105733 94724 0.216
Serum albumin (g/dl) 3.9270.61 3.4670.68 0.023
Systolic BP (mmHg) 125719 132718 0.202
Mesangial cellularity 1.6970.56 1.2570.26 0.002
Cronicity index 6.8473.53 7.0573.04 0.838
BP, blood pressure; eGFR, GFR estimated by Cockroft–Gault equation; FSGS, focal
segmental glomerulosclerosis; GN, glomerulonephritis; IgAN, immunoglobulin A
nephropathy; MC, minimal change glomerulonephritis; MesP, mesangioproliferative
glomerulonephritis; MN, membranous nephropathy; MP, membranoproliferative
glomerulonephritis.
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Figure 1 | Changes of proteinuria from baseline after
monotherapy and combination therapy in 21 patients with
(gray bars) non-proliferative and in 22 patients with
(white bars) proliferative GN.
Table 3 | Changes of main clinical and laboratory parameters
during follow-up
Baseline CEI CEI+ARB
Proteinuria (g/day) 3.5172.85 2.4272.32a 1.5171.33b,c
Body weight (kg) 75.4715.3 74.0713.0 74.6714.0
Serum albumin (g/dl) 3.6970.68 3.9770.62a 3.9870.65a
Systolic BP (mmHg) 128718 120722a 116718b
Diastolic BP (mmHg) 80712 76710 74712a
Serum creatinine (mg/dl) 1.0370.27 1.0670.33 1.1370.34d
eGFR (ml/min/1.73 m2) 100729 100732 94732d
Hemoglobin (g/dl) 13.971.6 14.071.5 13.871.3
Serum potassium (mEq/l) 4.570.3 4.570.4 4.670.5
Sodium excretion (mEq/day) 178771 180761 176791
ARB, angiotensin II receptor blocker; BP, blood pressure; CEI, converting enzyme
inhibitor; eGFR, GFR estimated by Cockroft–Gault equation.
aPo0.01 versus baseline.
bPo0.001 versus baseline.
cPo0.01 versus CEI.
dPo0.05 versus others.
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that detected after CEI alone (Table 2). Although BP values
declined in parallel with the enhancement of RAS inhibition,
no difference in the entity of BP control emerged between
the two phases of the study; this finding, which this study
shares with other works,8–12,23–26 suggests that the major anti-
proteinuric effect of combination therapy is largely indepen-
dent from its antihypertensive action. Similarly, the additive
effect of a lower salt intake on proteinuria reduction can be
excluded in this study because sodium excretion did not
change throughout the period of observation. Hence, the
present study confirms in patients with a variety of GNs that
combination therapy leads, on average, to a greater
antiproteinuric effect, which appears specifically related to a
more profound inhibition of RAS.
More important, a novel question here addressed is
whether the antiproteinuric response to CEIþARB is
unpredictable or depends on some particular characteristics
of patients. The additional value of combination treatment,
in fact, is not a consistent finding. Specifically, in non-
diabetic CKD, as in the case of our patients, a greater
antiproteinuric effect has been reported by studies that
exclusively, or for the most part, enrolled patients with
IgAN,8,9,11,23,24 while conflicting results have been obtained in
patients with non-proliferative GN.12,25,26 That combination
Table 4 | Distribution of demographic and clinical
characteristics according to responders and non-responders
to CEI+ARB
Responders
(n=21)
Non-responders
(n=22) P-value
At baseline
Age (years) 37.3718.1 39.0714.5 0.743
Male gender (%) 66.7 63.6 0.835
Body mass index (kg/m2) 26.073.8 26.274.3 0.894
Basal proteinuria (g/day) 3.8373.29 3.2072.39 0.472
Serum creatinine (mg/dl) 0.9670.27 1.0970.27 0.123
eGFR (ml/min/1.73 m2) 106733 95724 0.229
Serum albumin (g/dl) 3.6870.67 3.7170.71 0.890
Systolic BP (mmHg) 129721 128716 0.907
Diastolic BP (mmHg) 80714 80710 0.943
After treatment
D proteinuria (g/day) 2.9472.75 1.0971.07 0.008
D proteinuria (%) 75.6711.7 31.7713.7 o0.0001
D eGFR (%) 6.2717.5 7.6716.2 0.785
D systolic BP (%) 10.6710.3 7.779.7 0.352
D diastolic BP (%) 5.8712.4 6.4712.5 0.874
Sodium excretion (mEq/day) 184779 173764 0.666
ARB, angiotensin II receptor blocker; BP, blood pressure; CEI, converting enzyme
inhibitor; eGFR, GFR estimated by Cockroft–Gault equation; D, change versus
baseline.
Table 5 | Histological scores in responders and non-responders to CEI+ARB
Responders (n=21) Non-responders (n=22) P-value
Proliferative GN (% patients) 71.4 31.8 0.009
Diagnosis of GN 10 IgAN, 4 MesP, 1 MP, 5 MN, 1 FSGS 6 IgAN, 1 MesP, 8 MN, 6 FSGS, 1 MC —
Mesangial cellularity 1.7670.52 1.2070.22 o0.0001
Interstitial fibrosis 2.4870.80 2.0971.15 0.211
Tubular atrophy 2.2470.96 1.9371.20 0.361
Interstitial infiltrates 1.6270.95 1.2771.20 0.302
Glomerulosclerosis 1.9070.52 1.7770.77 0.513
Arteriosclerosis 0.5770.81 0.7371.07 0.594
Arteriolar hyalinosis 0.8871.22 0.8071.25 0.822
Cronicity index 7.3272.83 6.5873.65 0.462
ARB, angiotensin II receptor blocker; CEI, converting enzyme inhibitor; FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; IgAN, immunoglobulin A
nephropathy; MC, minimal change glomerulonephritis; MesP, mesangioproliferative glomerulonephritis; MN, membranous nephropathy; MP, membranoproliferative
glomerulonephritis.
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Figure 2 | Association between score of mesangial cellularity and
percentage changes of proteinuria after CEIþARB therapy
(r¼ 0.573; Po0.0001). Black circles identify patients with
non-proliferative GN, whereas open circles identify patients
with proliferative GN.
Table 6 | Multiple linear regression analysis of antiproteinuric
response to CEI+ARB
b Coefficient P-value
Constant 18.427 0.233
Age (years) 0.413 0.110
Gender (female as reference) 4.931 0.483
D systolic blood pressure (%) 0.514 0.130
D eGFR (%) 0.325 0.144
Mesangial score 27.603 0.001
Cronicity index 1.272 0.252
Type of GN (NP as reference) 11.251 0.155
ARB, angiotensin II receptor blocker; CEI, converting enzyme inhibitor; eGFR, GFR
estimated by Cockroft–Gault equation; GN, glomerulonephritis; NP, non-prolifera-
tive; D, change versus baseline.
Model summary: r2=0.476, F=4.540, P=0.001.
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therapy has different efficacy in subtypes of renal diseases has
also been hypothesized by the authors of the COOPERATE
study.11 Besides the published data, also in clinical practice, it
is common to observe incongruity in response to the dual
blockade of RAS.
We addressed this problem by evaluating for the first time
several clinopathologic correlates to antiproteinuric response
to combination therapy. Indeed, the efficacy of any
antiproteinuric intervention depends on several factors, such
as age, gender, length of treatment, and changes of BP or
GFR. It can also be influenced by less known clinical factors,
such as body mass index, serum albumin, and salt intake.27–29
Similarly, type and severity of renal lesions have an effect on
proteinuria independently from underlying GN.30–33 When
we categorized patients in responders and non-responders
to CEIþARB, no significant difference emerged from
the several demographic and clinical variables examined
(Table 3). In particular, a comparable pattern of changes of
both BP and estimated GFR was detected between the two
groups. Also, basal proteinuria level did not affect response.
Similarly, the antiproteinuric efficacy of combination was
not specifically related to diagnosis of IgAN.
On the other hand, the histological study provided
important information. We found similarities in cell
infiltrates and in the specific histological markers of cronicity
of GN, and of abnormalities of intrarenal arterial vessels as
well; these negative findings, therefore, exclude a role of acute
inflammation or senescence of renal structures in the quality
of response. In contrast, the subgroup of patients highly
responsive to CEIþARB was characterized by a significantly
greater prevalence of proliferative GNs. Indeed, these patients
showed a greater decrement of proteinuria after CEIþARB
with respect to those with non-proliferative GN (Figure 1).
Similarly, a significantly higher mesangial score was detected
in responders. Indeed, as depicted in Figure 2, entity of
mesangial cellularity and magnitude of antiproteinuric effect
of dual RAS suppression strictly correlated with the
association being similar in proliferative and non-prolifera-
tive GNs. Hence, the degree of mesangial cellularity
influences response independently from the type of glomer-
ular disease. To gain more insights into the independent role
of these two histological figures – type of GN and mesangial
score – a multiple regression analysis was run. The results
confirm that the entity of mesangial cellularity is the sole
independent predictor of the antiproteinuric response to dual
blockade of RAS.
These findings therefore disclose a linkage between
mesangial cellularity and AII. The contribution of AII in the
pathophysiology of proteinuria and progression of primary
GNs has been amply described.20,34–36 A recent study,
moreover, has provided evidence that the glomerular expres-
sion of angiotensin-converting enzyme, chymase, and AII
receptors correlates with the degree of mesangial hypercellu-
larity in patients with IgAN, suggesting that locally synthe-
sized AII is involved in this renal lesion.37 Indeed, the
mitogenic effect of AII on cultured mesangial cells is known
from long time.38,39 In addition, mesangial hypercellularity is
associated with high sensitivity to the beneficial effects of CEI
and ARB on glomerular structure and function,35 whereas
lysis of mesangial cells prevents any glomerular effect of AII.40
Of note, mesangial hypercellularity is not limited to
proliferative GNs, but it can also be observed in non-
proliferative GNs, as in the case of this study. This occurs
possibly because of the stimulation of intrarenal AII
production secondary to the tubular overload of proteins.41,42
Hence, the higher response to CEIþARB in the presence of
mesangial hypercellularity suggests that this lesion is, at least
in part, determined by high intrarenal AII levels.
Limitations of the study are mainly inherent to the small
sample size and the retrospective nature of analysis. There-
fore, the results obtained, while reflecting clinical practice,
should be confirmed by large prospective clinical trials.
Furthermore, effectiveness of ARB alone was not investigated;
nevertheless, several previous studies have shown analogous
efficacy of ARB and CEI monotherapies.8–12,23–26 Slightly
different therapeutic regimens were also used; however, drug
doses were therapeutically equivalent and analysis excluded a
specific drug effect in agreement with the previous
studies.8–10 Finally, results may not be extrapolated to
patients with advanced kidney disease or patients treated
with immunosuppressive agents; on the other hand, this
exclusion is compatible with the aim of this study that
required adequate analysis of the morphological lesions.
Conclusion
This study provides evidence that in heterogeneous popula-
tion of GN patients, the antiproteinuric effect of dual
blockade of RAS is significantly greater in proliferative than
in non-proliferative GNs. The best independent predictor of
antiproteinuric response to CEIþARB is the extent of
mesangial cellularity. A reasonable explanation to this finding
is that, as suggested in experimental studies, high intrarenal
AII levels contribute to mesangial hypercellularity. Such a
specific lesion therefore identifies patients who will gain most
benefit from the combination therapy. In this subgroup of
patients, the beneficial effect of intense RAS inhibition is
probably not limited to the larger reduction of proteinuria;
evidence has been in fact collected on the possibility to attain
by means of RAS suppression the regression of renal disease,
with the reversal of mesangial hypercellularity being a main
initial event.3,36,43–45
MATERIALS AND METHODS
Patients
We conducted in three Nephrology Units (Second University of
Naples, University Federico II of Naples, and University of
Catanzaro) a retrospective analysis of all consecutive patients with
primary biopsy-proven GN, which in the first semester of 2005 were
treated with combination therapy (CEIþARB) because of protein-
uria 40.5 g/day, persistent after CEI alone.
Secondary GN forms were excluded according to traditional
histological, clinical, and serological criteria. Additional exclusion
criteria were: previous therapy, at any point of time of the clinical
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history, with either steroids or immunosuppressive agents, treat-
ment with RAS inhibitors before biopsy, delayed treatment with CEI
(started more than 6 months after biopsy), treatment with either
CEI or CEIþARB lasting less than 2 months, inadequate biopsy
specimen (less than seven glomeruli and one artery), incomplete
collection of essential data, or inaccurate 24-h urine collection.
Clinical data
Data were extracted from clinical charts at three time points: last
available evaluation after biopsy and before starting CEI (BASAL),
last available evaluation of the effects of CEI monotherapy before
prescription of combined therapy (CEI), and last evaluation of the
effects of combination therapy performed in the first semester of
2005 (CEIþARB). Data considered essential for the analysis at each
time point of the study were: age, gender, body weight, BP,
therapeutic regimen, serum levels of creatinine, albumin, and pota-
ssium, hemoglobin, 24-h urinary excretion of sodium, creatinine,
and proteins.
The three participating centers shared the following routine
features: presence of outpatient clinic dedicated to the conservative
care of CKD; presence of clinical and laboratory standardized
protocols, including three consecutive measurements of BP by a
mercury sphygmomanometer (in the morning before drug admin-
istration) 5 min apart in sitting position after 10 min of rest,
with Korotkoff phases I and V defining systolic and diastolic
values, repeated after 5 min in standing position to detect
orthostatic hypotension; measurement of creatinine in plasma
and urine performed by means of the modified kinetic Jaffe´
reaction; and measurement of proteinuria by pyrogallol red-
molibdate method.
Twenty-four hour urine collection was considered inaccurate if
the value of measured creatinine excretion rate was outside the
60–140% range of the value calculated according to Dwyer and
Kenler.46 Daily salt intake (g/day) was calculated dividing 24-h
urinary sodium excretion by 17. We estimated GFR by Cockcroft
and Gault equation because our patients had normal or nearly
normal renal function, and under these conditions, 24-h measured
creatinine clearance overestimates GFR, whereas Modification of
Diet in Renal Disease equation adequately predicts GFR in patients
with more advanced CKD.14,47 The GFR value was standardized to a
body surface area of 1.73 m2.
The median of percent reduction of Uprot after CEIþARB
(53%, range 4–95) was used to classify patients in responders (Uprot
decrease 453%) and non-responders (Uprot decrease p53%).
Kidney biopsy study
Two investigators independently reviewed kidney biopsies, and the
means of individual scores were used for analysis. Diagnosis and
classification of GN (proliferative and non-proliferative) were made
according to traditional criteria.48 Light microscopical changes were
semiquantitatively estimated according to a scoring system pre-
viously used by our group,49 which is partly based on the Banff
schema.50,51 The following variables were graded (0, 1, 2, and 3 that
correspond to normal, mild, moderate, and severe, respectively):
interstitial fibrosis/tubular atrophy, interstitial mononuclear cell
infiltration glomerulosclerosis (GSC), arteriosclerosis, and arteriolar
hyalinosis. In particular, we graded interstitial fibrosis/tubular
atrophy and mononuclear cell infiltration on the basis of the extent
of involved area, GSC on the basis of number of involved glomeruli
and intraglomerular extent of sclerosis, arteriosclerosis on the basis
of severity of the fibrointimal thickening of arteries, and arteriolar
hyalinosis on the basis of the percentage of the circumference of
arterioles affected by periodic acid Schiff-positive insudation or
hyaline thickening. The cronicity index of each biopsy was defined
by the sum of the scores of arteriosclerosisþ arteriolar hyalino-
sisþGSCþmononuclear cell infiltrationþ interstitial fibrosis/
tubular atrophy. We also graded mesangial proliferation on the basis
of the number of mesangial cells per mesangial area (score 1¼ 0–3
cells, score 2¼ 4–5 cells, score 3¼ 6–7 cells, and score 4¼X8 cells);
each score was multiplied for the number of glomeruli with that
score and then normalized for the total number of glomeruli
according to the following formula:
Mesangial score ¼ NG1=TNGþ NG2=TNGþ NG3=TNG
þ NG4=TNG
where NG1–4 is the number of glomeruli with that specific score
(1–4) and TNG is the total number of glomeruli.
Statistical analysis
Values are reported as mean7s.d. We used for analysis of
continuous variables only parametric methods because Shapiro–-
Wilk test did not reject the hypothesis of normal distribution.
Differences between responders and non-responders were evaluated
by unpaired Student’s t-test, whereas paired Student’s t-test was used
to detect intragroup differences. Analysis of variance for repeated
measurements was used to compare data at baseline, after CEI, and
after CEIþARB. Bonferroni post hoc test was also used. Multiple
linear regression analysis was used to identify the predictors of
antiproteinuric response (percent changes of proteinuria from
baseline) to CEIþARB. The model was built by identifying a priori
the main potential determinants of antiproteinuric response among
demographic features (age and gender), laboratory and clinical
variables (percent changes of estimated GFR and systolic BP), and
histological patterns (mesangial score, cronicity index, and type of
GN – proliferative, non-proliferative). Pearson’s correlation coeffi-
cient was also used. Agreement between the two observers on
histological scores was verified by kappa index.52 Data were analyzed
using SAS version 8.1 (SAS Inc., Cary, NC, USA). Po0.05 was
considered statistically significant.
REFERENCES
1. El Nahas AM, Bello AK. Chronic kidney disease: the global challenge.
Lancet 2005; 365: 331–340.
2. De Jong PE, Navis G, de Zeeuw D. Renoprotective therapy: titration
against urinary protein excretion. Lancet 1999; 354: 352–353.
3. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and
regression of renal lesions of chronic nephropathies and diabetes. J Clin
Invest 2006; 116: 288–296.
4. Ruggenenti P, Perna A, Mosconi L et al. Urinary protein excretion rate is
the best independent predictor of ESRF in non-diabetic proteinuric
chronic nephropathies. Kidney Int 1998; 53: 1209–1216.
5. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of
developing end-stage renal disease. Kidney Int 2003; 63: 1468–1474.
6. Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for
advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131–140.
7. Ruggenenti P, Perna A, Remuzzi G et al. ACE inhibitors to prevent
end-stage renal disease: when to start and why possibly never to stop:
a post hoc analysis of the REIN trial results. J Am Soc Nephrol 2001; 12:
2832–2837.
8. Russo D, Pisani A, Balletta MM et al. Additive antiproteinuric effect of
converting enzyme inhibitor and losartan in normotensive patients with
IgA nephropathy. Am J Kidney Dis 1999; 33: 851–856.
9. Russo D, Minutolo R, Pisani A et al. Coadministration of losartan and
enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J
Kidney Dis 2001; 38: 18–25.
Kidney International (2006) 70, 1170–1176 1175
R Minutolo et al.: Predictors of response to CEIþARB o r i g i n a l a r t i c l e
10. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin
II receptor blockers to halt progression of chronic kidney disease:
pathophysiology and indications. Kidney Int 2005; 67: 799–812.
11. Nakao N, Yoshimura A, Morita H et al. Combination treatment of
angiotensin II receptor blocker and angiotensin-converting enzyme
inhibitor in non-diabetic renal disease (COOPERATE): a randomised
controlled trial. Lancet 2003; 361: 117–124.
12. Iodice C, Balletta MM, Minutolo R et al. Maximal suppression of
renin–angiotensin system in non-proliferative glomerulonephritis. Kidney
Int 2003; 63: 2214–2221.
13. De Nicola L, Minutolo R, Gallo C et al. Management of hypertension in
chronic kidney disease: the Italian Multicentric Study. J Nephrol 2005; 18:
397–404.
14. De Nicola L, Minutolo R, Chiodini P et al. Global approach to
cardiovascular risk in chronic kidney disease: reality and opportunities for
intervention. Kidney Int 2006; 69: 538–545.
15. K/DOQI clinical practice guidelines on hypertension and antihypertensive
agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1–S290.
16. Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the
renin–angiotensin system and other antihypertensive drugs on renal
outcomes: systematic review and meta-analysis. Lancet 2005; 366:
2026–2033.
17. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of
angiotensins I and II in anesthetized rats. Hypertension 2002; 39: 129–134.
18. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid angiotensin I and
angiotensin II concentrations during local angiotensin-converting
enzyme inhibition. J Am Soc Nephrol 2002; 13: 2207–2212.
19. Hollemberg NK, Fisher NDL, Price DA. Pathways for angiotensin II
generation in intact human tissue. Evidence from comparative
pharmacological interruption of the renin system. Hypertension 1998;
32: 387–392.
20. Takashi E, Shigematsu H. Contribution of mast cells to the tubulointer-
stitial lesions in IgA nephritis. Kidney Int 1998; 54: 1675–1683.
21. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in
diabetic nephropathy: implications for an alternative pathway of
angiotensin II-mediated diabetic renal and vascular disease. J Am Soc
Nephrol 2003; 14: 1738–1747.
22. Komine N, Khang S, Wead LM et al. Effect of combining an ACE inhibitor
and an angiotensin II receptor blocker on plasma and kidney tissue
angiotensin II levels. Am J Kidney Dis 2002; 39: 159–164.
23. Campbell R, Sangalli F, Perticucci E et al. Effects of combined ACE
inhibitor and angiotensin II antagonist treatment in human chronic
nephropaties. Kidney Int 2003; 63: 1094–1103.
24. Rutkowski P, Tylicki L, Renke M et al. Low-dose dual blockade of the
renin–angiotensin system in patients with primary glomerulonephritis.
Am J Kidney Dis 2004; 43: 260–268.
25. Laverman GD, Navis G, Henning RH et al. Dual renin–angiotensin system
blockade at optimal doses for proteinuria. Kidney Int 2002; 62: 1020–1025.
26. Ferrari P, Marti HP, Pfister M, Frey FJ. Additive antiproteinuric effect
of combined ACE inhibition and angiotensin II receptor blockade.
J Hypertension 2002; 20: 125–130.
27. Morales E, Valero MA, Leon M et al. Beneficial effects of weight loss in
overweight patients with chronic proteinuric nephropaties. Am J Kidney
Dis 2003; 41: 319–327.
28. Praga M, Borstein B, Andres A et al. Nephrotic proteinuria without
hypoalbuminemia: clinical characteristics and response to
angiotensin-converting enzyme inhibition. Am J Kidney Dis 1991; 17:
330–338.
29. Weir MR, Fink JC. Salt intake and progression of chronic kidney disease:
an overlooked modifiable exposure? A commentary. Am J Kidney Dis
2004; 45: 176–188.
30. Cattran D. Predicting outcome in the idiopathic glomerulopathies.
J Nephrol 1998; 11: 57–60.
31. Dumoulin A, Hill GS, Montseny JJ, Meyrier A. Clinical and morphological
prognostic factors in membranous nephropathy: significance of focal
segmental glomerulosclerosis. Am J Kidney Dis 2003; 41: 38–48.
32. Lee HS, Lee MS, Lee SM et al. Histological grading of IgA nephropathy
predicting renal outcome: revisiting HS Lee’s glomerular grading system.
Nephrol Dial Transplant 2005; 20: 342–348.
33. Lufft V, Kliem V, Hamkens A et al. Antiproteinuric efficacy of lisinopril after
renal transplantation is determined by the extent of vascular and
tubulointerstitial damage. Clin Transplant 1998; 12: 409–415.
34. Remuzzi A, Perico N, Sangalli F et al. ACE inhibition and ANG II receptor
blockade improve glomerular size-selectivity in IgA nephropathy. Am J
Physiol 1999; 276: F457–F466.
35. Nakamura T, Obata J, Kimura H et al. Blocking angiotensin II ameliorates
proteinuria and glomerular lesions in progressive mesangioproliferative
glomerulonephritis. Kidney Int 1999; 55: 877–889.
36. Tanaka H, Suzuki K, Nakahata T et al. Combined therapy of enalapril
and losartan attenuates histologic progression in immunoglobulin
A nephropathy. Pediatr Int 2004; 46: 576–579.
37. Ogawa-Miyake C, Miyazaki M, Abe K et al. Tissue-specific expression of
renin–angiotensin system components in IgA nephropathy. Am J Nephrol
2005; 25: 1–12.
38. Ray PE, Aguilera G, Kopp JB et al. Angiotensin receptor-mediated
proliferation of cultured human fetal mesangial cells. Kidney Int 1991; 40:
764–771.
39. Wolf G, Haberstroh U, Neilson EG. Angiotensin II stimulates the
proliferation and biosynthesis of type I collagen in cultured murine
mesangial cells. Am J Pathol 1992; 140: 95–107.
40. Blantz RC, Gabbai FB, Tucker BJ et al. Role of mesangial cell in glomerular
response to volume and angiotensin II. Am J Physiol 1993; 264:
F158–F165.
41. Go´mez-Garre D, Largo R, Tejera N et al. Activation of NF-kB in tubular
epithelial cells of rats with intense proteinuria. Role of angiotensin II and
endothelin-1. Hypertension 2001; 37: 1171–1178.
42. Largo R, Go´mez-Garre D, Soto K et al. Angiotensin converting enzyme is
upregulated in the proximal tubules of rats with intense proteinuria.
Hypertension 1999; 33: 732–739.
43. Hotta O, Furuta T, Chiba S et al. Regression of IgA nephropathy. A repeat
biopsy study. Am J Kidney Dis 2002; 39: 493–502.
44. Adamczak M, Gross ML, Amann K, Ritz E. Reversal of glomerular lesions
involves coordinated restructuring of glomerular microvasculature. J Am
Soc Nephrol 2004; 15: 3063–3072.
45. Fogo AB. Progression versus regression of chronic kidney disease.
Nephrol Dial Transplant 2006; 21: 281–284.
46. Dwyer J, Kenler SR. Assessment of nutritional status in renal disease. In:
Mitch WE, Klahr S (eds). Nutrition and the Kidney. 2nd edn. Little, Brown
and Company: Boston, MA, 1993 pp 61–95.
47. Levey AS, Bosch JP, Breyer Lewis J et al. A more accurate method to
estimate glomerular filtration rate from serum creatinine: a new
prediction equation. Ann Intern Med 1999; 130: 461–470.
48. Hricik DE, Chung P, Sedor JR. Glomerulonephritis. N Engl J Med 1998; 339:
888–899.
49. Fuiano G, Sund S, Mazza G et al. Renal hemodynamic response to
maximal vasodilating stimulus in healthy elderly subjects. Kidney Int 2001;
59: 1052–1058.
50. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of
renal allograft pathology. Kidney Int 1999; 55: 713–723.
51. Sund S, Reisaeter AV, Scott H et al. Morphological studies of baseline
needle biopsies from living donor kidneys: light microscopic,
immunohistochemical and ultrastructural findings. APMIS 1998; 106:
1017–1034.
52. Svanholm H, Starklint H, Gundersen HJG et al. Reproducibility of
histomorphologic diagnoses with special reference to the kappa statistic.
APMIS 1989; 97: 689–698.
1176 Kidney International (2006) 70, 1170–1176
o r i g i n a l a r t i c l e R Minutolo et al.: Predictors of response to CEIþARB
